Vyaire Medical, a medical device maker, has announced the availability of SuperNO2VA Et, a mask featuring technology to stent the airway open. This innovation avoids airway collapse while accurately monitoring end tidal carbon dioxide (EtCO2), which is particularly important for high-risk patients undergoing surgery.
“SuperNO2VA Et brings a new standard to the way surgeries can be performed for patients,” says Steven H. Cataldo, MD, director of anesthesiology at CareMount Medical and director of anesthesia services at Yorktown Center for Specialty Surgery in New York. “With this technology, we are able to rethink how and where we operate, with decreased risks, procedure times, and associated costs. Even high-risk patients can have reduced recovery times, providing them a safer and better overall care experience.”
The mask is designed to maintain airway patency while delivering precise and consistent oxygenation to patients during deep sedation procedures, which helps reduce hypoxemia and hypoventilation. SuperNO2VA Et provides continuous patient oxygenation before, during, and after surgery, which allows more patients to have procedures under sedation.
“At Vyaire, we are committed to imagining new possibilities in the ways we can support breathing,” says Gaurav Agarwal, CEO of Vyaire. “SuperNO2VA Et does just that by removing some of the tangible risks of deep sedation through proprietary airway management technology and real-time clinical measurements to reduce complications. Through this innovation, we envision reducing the need for general anesthesia and the associated complications, including extended procedure times, hospital stays, and their burdens on healthcare systems.”
SuperNO2VA Et reduces hypoxemia by 75% and airway intervention by 65% compared to the current standard of care.[1,2] It also allows for effective pre-oxygenation and rescue ventilation without the need for additional equipment. The mask eliminates the use and associated costs of a separate mask, endotracheal tube, laryngoscope, and intubation, according to the company.
“As the company inspired and empowered to elevate the quality of breathing, SuperNO2VA Et is an obvious yet critical piece of our innovation strategy and evolution,” Agarwal says. “We will continue to bring new-to-world technology to market to advance breathing solutions on behalf of customers and patients.”
- Bai Y., Xu Z., Chandrashekar M., et al. Comparison of a simplified nasal continuous positive airways pressure device with nasal cannula in obese patients undergoing colonoscopy during deep sedation: A randomised clinical trial. Eur J Anaesthesiol. 2019;36(9):633-640.
- Dimou F., Huynh S., Dakin G., et al. Nasal positive pressure with the SuperNO2VA Et device decreases sedation-related hypoxemia during pre-bariatric surgery EGD. Surg Endosc. 2019;33(11):3828-3832.